Novartis pharma sales down in 4Q, but Alcon and Sandoz units see profits
This article was originally published in Scrip
Novartis's pharmaceutical sales struggled in the fourth quarter of 2014 because of increased generic competition, but its own generics division Sandoz and ophthalmology unit Alcon both saw increases in the quarter.
You may also be interested in...
Health care funding in the first half of 2020 reached $10.4bn, according to a mid-year report from Silicon Valley Bank, nearly matching 2019’s full-year record. As well as the COVID-19 pandemic though, other global events, such as the US election, could become distractions in the second half of the year.
In this latest installment of VC Playbook, Chris Buyse – former chief financial officer of ThromboGenics – talks to In Vivo about the lessons he has learned from a career as a financial executive in the life sciences and his current venture, Fund+, a Belgian-based investment group focused on innovative companies primarily active in therapeutics R&D.
A selection of articles you might have missed from July 2020, including exclusive interviews with industry leaders and a review of Q2 financing statistics.